The Quinolones
Summary The fluoroquinolones represent a relatively new class of antibiotics with outstanding therapeutic potential, attributable to their broad spectrum of antimicrobial activity and favourable tissue distribution. They are highly active against most Gram-negative pathogens, as well as Staphylococc...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Fitton, Andrew [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1992 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Clinical pharmacokinetics - Berlin [u.a.] : Springer, 1976, 22(1992), Suppl 1 vom: Juni, Seite 1-11 |
|---|---|
| Übergeordnetes Werk: |
volume:22 ; year:1992 ; number:Suppl 1 ; month:06 ; pages:1-11 |
| Links: |
|---|
| DOI / URN: |
10.2165/00003088-199200221-00003 |
|---|
| Katalog-ID: |
SPR03303950X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR03303950X | ||
| 003 | DE-627 | ||
| 005 | 20230519182346.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s1992 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2165/00003088-199200221-00003 |2 doi | |
| 035 | |a (DE-627)SPR03303950X | ||
| 035 | |a (SPR)00003088-199200221-00003-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.00 |2 bkl | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Fitton, Andrew |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Quinolones |
| 264 | 1 | |c 1992 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Summary The fluoroquinolones represent a relatively new class of antibiotics with outstanding therapeutic potential, attributable to their broad spectrum of antimicrobial activity and favourable tissue distribution. They are highly active against most Gram-negative pathogens, as well as Staphylococcus aureus and coagulase-negative staphylococci. In addition, the fluoroquinolones have useful pharmacokinetic properties: they are orally active, and their lipophilicity and low degree of plasma protein binding allow for excellent tissue penetration and concentrations, as reflected in their particularly large apparent volumes of distribution. Infections due to aerobic Gram-negative pathogens are considered those most susceptible to the quinolones. Disease indications in which these agents appear to offer the greatest therapeutic advantage over currently available alternatives include the following: complicated urinary tract infections (particularly those caused by Pseudomonas aeruginosa or resistant Gram-negative microorganisms); suspected bacterial gastroenteritis; eradication of Salmonella typhi from the faeces in known carriers; P. aeruginosa-associated respiratory exacerbation in patients with cystic fibrosis; and chronic Gram-negative bacterial osteomyelitis. Direct comparisons of the various quinolones are too limited to date to provide clear therapeutic options. Nevertheless, this class of compounds is likely to play a major role in providing effective oral therapy for conditions that have previously required prolonged parenteral treatment. | ||
| 650 | 4 | |a Fluoroquinolones |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Ofloxacin |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Norfloxacin |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Chlamydia Trachomatis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Antimicrobial Chemotherapy |7 (dpeaa)DE-He213 | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical pharmacokinetics |d Berlin [u.a.] : Springer, 1976 |g 22(1992), Suppl 1 vom: Juni, Seite 1-11 |w (DE-627)327644974 |w (DE-600)2043781-X |x 1179-1926 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:1992 |g number:Suppl 1 |g month:06 |g pages:1-11 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.2165/00003088-199200221-00003 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2190 | ||
| 936 | b | k | |a 44.00 |q ASE |
| 936 | b | k | |a 44.40 |q ASE |
| 951 | |a AR | ||
| 952 | |d 22 |j 1992 |e Suppl 1 |c 06 |h 1-11 | ||
| author_variant |
a f af |
|---|---|
| matchkey_str |
article:11791926:1992----::hqio |
| hierarchy_sort_str |
1992 |
| bklnumber |
44.00 44.40 |
| publishDate |
1992 |
| allfields |
10.2165/00003088-199200221-00003 doi (DE-627)SPR03303950X (SPR)00003088-199200221-00003-e DE-627 ger DE-627 rakwb eng 610 ASE 44.00 bkl 44.40 bkl Fitton, Andrew verfasserin aut The Quinolones 1992 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary The fluoroquinolones represent a relatively new class of antibiotics with outstanding therapeutic potential, attributable to their broad spectrum of antimicrobial activity and favourable tissue distribution. They are highly active against most Gram-negative pathogens, as well as Staphylococcus aureus and coagulase-negative staphylococci. In addition, the fluoroquinolones have useful pharmacokinetic properties: they are orally active, and their lipophilicity and low degree of plasma protein binding allow for excellent tissue penetration and concentrations, as reflected in their particularly large apparent volumes of distribution. Infections due to aerobic Gram-negative pathogens are considered those most susceptible to the quinolones. Disease indications in which these agents appear to offer the greatest therapeutic advantage over currently available alternatives include the following: complicated urinary tract infections (particularly those caused by Pseudomonas aeruginosa or resistant Gram-negative microorganisms); suspected bacterial gastroenteritis; eradication of Salmonella typhi from the faeces in known carriers; P. aeruginosa-associated respiratory exacerbation in patients with cystic fibrosis; and chronic Gram-negative bacterial osteomyelitis. Direct comparisons of the various quinolones are too limited to date to provide clear therapeutic options. Nevertheless, this class of compounds is likely to play a major role in providing effective oral therapy for conditions that have previously required prolonged parenteral treatment. Fluoroquinolones (dpeaa)DE-He213 Ofloxacin (dpeaa)DE-He213 Norfloxacin (dpeaa)DE-He213 Chlamydia Trachomatis (dpeaa)DE-He213 Antimicrobial Chemotherapy (dpeaa)DE-He213 Enthalten in Clinical pharmacokinetics Berlin [u.a.] : Springer, 1976 22(1992), Suppl 1 vom: Juni, Seite 1-11 (DE-627)327644974 (DE-600)2043781-X 1179-1926 nnns volume:22 year:1992 number:Suppl 1 month:06 pages:1-11 https://dx.doi.org/10.2165/00003088-199200221-00003 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.00 ASE 44.40 ASE AR 22 1992 Suppl 1 06 1-11 |
| spelling |
10.2165/00003088-199200221-00003 doi (DE-627)SPR03303950X (SPR)00003088-199200221-00003-e DE-627 ger DE-627 rakwb eng 610 ASE 44.00 bkl 44.40 bkl Fitton, Andrew verfasserin aut The Quinolones 1992 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary The fluoroquinolones represent a relatively new class of antibiotics with outstanding therapeutic potential, attributable to their broad spectrum of antimicrobial activity and favourable tissue distribution. They are highly active against most Gram-negative pathogens, as well as Staphylococcus aureus and coagulase-negative staphylococci. In addition, the fluoroquinolones have useful pharmacokinetic properties: they are orally active, and their lipophilicity and low degree of plasma protein binding allow for excellent tissue penetration and concentrations, as reflected in their particularly large apparent volumes of distribution. Infections due to aerobic Gram-negative pathogens are considered those most susceptible to the quinolones. Disease indications in which these agents appear to offer the greatest therapeutic advantage over currently available alternatives include the following: complicated urinary tract infections (particularly those caused by Pseudomonas aeruginosa or resistant Gram-negative microorganisms); suspected bacterial gastroenteritis; eradication of Salmonella typhi from the faeces in known carriers; P. aeruginosa-associated respiratory exacerbation in patients with cystic fibrosis; and chronic Gram-negative bacterial osteomyelitis. Direct comparisons of the various quinolones are too limited to date to provide clear therapeutic options. Nevertheless, this class of compounds is likely to play a major role in providing effective oral therapy for conditions that have previously required prolonged parenteral treatment. Fluoroquinolones (dpeaa)DE-He213 Ofloxacin (dpeaa)DE-He213 Norfloxacin (dpeaa)DE-He213 Chlamydia Trachomatis (dpeaa)DE-He213 Antimicrobial Chemotherapy (dpeaa)DE-He213 Enthalten in Clinical pharmacokinetics Berlin [u.a.] : Springer, 1976 22(1992), Suppl 1 vom: Juni, Seite 1-11 (DE-627)327644974 (DE-600)2043781-X 1179-1926 nnns volume:22 year:1992 number:Suppl 1 month:06 pages:1-11 https://dx.doi.org/10.2165/00003088-199200221-00003 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.00 ASE 44.40 ASE AR 22 1992 Suppl 1 06 1-11 |
| allfields_unstemmed |
10.2165/00003088-199200221-00003 doi (DE-627)SPR03303950X (SPR)00003088-199200221-00003-e DE-627 ger DE-627 rakwb eng 610 ASE 44.00 bkl 44.40 bkl Fitton, Andrew verfasserin aut The Quinolones 1992 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary The fluoroquinolones represent a relatively new class of antibiotics with outstanding therapeutic potential, attributable to their broad spectrum of antimicrobial activity and favourable tissue distribution. They are highly active against most Gram-negative pathogens, as well as Staphylococcus aureus and coagulase-negative staphylococci. In addition, the fluoroquinolones have useful pharmacokinetic properties: they are orally active, and their lipophilicity and low degree of plasma protein binding allow for excellent tissue penetration and concentrations, as reflected in their particularly large apparent volumes of distribution. Infections due to aerobic Gram-negative pathogens are considered those most susceptible to the quinolones. Disease indications in which these agents appear to offer the greatest therapeutic advantage over currently available alternatives include the following: complicated urinary tract infections (particularly those caused by Pseudomonas aeruginosa or resistant Gram-negative microorganisms); suspected bacterial gastroenteritis; eradication of Salmonella typhi from the faeces in known carriers; P. aeruginosa-associated respiratory exacerbation in patients with cystic fibrosis; and chronic Gram-negative bacterial osteomyelitis. Direct comparisons of the various quinolones are too limited to date to provide clear therapeutic options. Nevertheless, this class of compounds is likely to play a major role in providing effective oral therapy for conditions that have previously required prolonged parenteral treatment. Fluoroquinolones (dpeaa)DE-He213 Ofloxacin (dpeaa)DE-He213 Norfloxacin (dpeaa)DE-He213 Chlamydia Trachomatis (dpeaa)DE-He213 Antimicrobial Chemotherapy (dpeaa)DE-He213 Enthalten in Clinical pharmacokinetics Berlin [u.a.] : Springer, 1976 22(1992), Suppl 1 vom: Juni, Seite 1-11 (DE-627)327644974 (DE-600)2043781-X 1179-1926 nnns volume:22 year:1992 number:Suppl 1 month:06 pages:1-11 https://dx.doi.org/10.2165/00003088-199200221-00003 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.00 ASE 44.40 ASE AR 22 1992 Suppl 1 06 1-11 |
| allfieldsGer |
10.2165/00003088-199200221-00003 doi (DE-627)SPR03303950X (SPR)00003088-199200221-00003-e DE-627 ger DE-627 rakwb eng 610 ASE 44.00 bkl 44.40 bkl Fitton, Andrew verfasserin aut The Quinolones 1992 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary The fluoroquinolones represent a relatively new class of antibiotics with outstanding therapeutic potential, attributable to their broad spectrum of antimicrobial activity and favourable tissue distribution. They are highly active against most Gram-negative pathogens, as well as Staphylococcus aureus and coagulase-negative staphylococci. In addition, the fluoroquinolones have useful pharmacokinetic properties: they are orally active, and their lipophilicity and low degree of plasma protein binding allow for excellent tissue penetration and concentrations, as reflected in their particularly large apparent volumes of distribution. Infections due to aerobic Gram-negative pathogens are considered those most susceptible to the quinolones. Disease indications in which these agents appear to offer the greatest therapeutic advantage over currently available alternatives include the following: complicated urinary tract infections (particularly those caused by Pseudomonas aeruginosa or resistant Gram-negative microorganisms); suspected bacterial gastroenteritis; eradication of Salmonella typhi from the faeces in known carriers; P. aeruginosa-associated respiratory exacerbation in patients with cystic fibrosis; and chronic Gram-negative bacterial osteomyelitis. Direct comparisons of the various quinolones are too limited to date to provide clear therapeutic options. Nevertheless, this class of compounds is likely to play a major role in providing effective oral therapy for conditions that have previously required prolonged parenteral treatment. Fluoroquinolones (dpeaa)DE-He213 Ofloxacin (dpeaa)DE-He213 Norfloxacin (dpeaa)DE-He213 Chlamydia Trachomatis (dpeaa)DE-He213 Antimicrobial Chemotherapy (dpeaa)DE-He213 Enthalten in Clinical pharmacokinetics Berlin [u.a.] : Springer, 1976 22(1992), Suppl 1 vom: Juni, Seite 1-11 (DE-627)327644974 (DE-600)2043781-X 1179-1926 nnns volume:22 year:1992 number:Suppl 1 month:06 pages:1-11 https://dx.doi.org/10.2165/00003088-199200221-00003 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.00 ASE 44.40 ASE AR 22 1992 Suppl 1 06 1-11 |
| allfieldsSound |
10.2165/00003088-199200221-00003 doi (DE-627)SPR03303950X (SPR)00003088-199200221-00003-e DE-627 ger DE-627 rakwb eng 610 ASE 44.00 bkl 44.40 bkl Fitton, Andrew verfasserin aut The Quinolones 1992 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary The fluoroquinolones represent a relatively new class of antibiotics with outstanding therapeutic potential, attributable to their broad spectrum of antimicrobial activity and favourable tissue distribution. They are highly active against most Gram-negative pathogens, as well as Staphylococcus aureus and coagulase-negative staphylococci. In addition, the fluoroquinolones have useful pharmacokinetic properties: they are orally active, and their lipophilicity and low degree of plasma protein binding allow for excellent tissue penetration and concentrations, as reflected in their particularly large apparent volumes of distribution. Infections due to aerobic Gram-negative pathogens are considered those most susceptible to the quinolones. Disease indications in which these agents appear to offer the greatest therapeutic advantage over currently available alternatives include the following: complicated urinary tract infections (particularly those caused by Pseudomonas aeruginosa or resistant Gram-negative microorganisms); suspected bacterial gastroenteritis; eradication of Salmonella typhi from the faeces in known carriers; P. aeruginosa-associated respiratory exacerbation in patients with cystic fibrosis; and chronic Gram-negative bacterial osteomyelitis. Direct comparisons of the various quinolones are too limited to date to provide clear therapeutic options. Nevertheless, this class of compounds is likely to play a major role in providing effective oral therapy for conditions that have previously required prolonged parenteral treatment. Fluoroquinolones (dpeaa)DE-He213 Ofloxacin (dpeaa)DE-He213 Norfloxacin (dpeaa)DE-He213 Chlamydia Trachomatis (dpeaa)DE-He213 Antimicrobial Chemotherapy (dpeaa)DE-He213 Enthalten in Clinical pharmacokinetics Berlin [u.a.] : Springer, 1976 22(1992), Suppl 1 vom: Juni, Seite 1-11 (DE-627)327644974 (DE-600)2043781-X 1179-1926 nnns volume:22 year:1992 number:Suppl 1 month:06 pages:1-11 https://dx.doi.org/10.2165/00003088-199200221-00003 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.00 ASE 44.40 ASE AR 22 1992 Suppl 1 06 1-11 |
| language |
English |
| source |
Enthalten in Clinical pharmacokinetics 22(1992), Suppl 1 vom: Juni, Seite 1-11 volume:22 year:1992 number:Suppl 1 month:06 pages:1-11 |
| sourceStr |
Enthalten in Clinical pharmacokinetics 22(1992), Suppl 1 vom: Juni, Seite 1-11 volume:22 year:1992 number:Suppl 1 month:06 pages:1-11 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Fluoroquinolones Ofloxacin Norfloxacin Chlamydia Trachomatis Antimicrobial Chemotherapy |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Clinical pharmacokinetics |
| authorswithroles_txt_mv |
Fitton, Andrew @@aut@@ |
| publishDateDaySort_date |
1992-06-01T00:00:00Z |
| hierarchy_top_id |
327644974 |
| dewey-sort |
3610 |
| id |
SPR03303950X |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR03303950X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519182346.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1992 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00003088-199200221-00003</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR03303950X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00003088-199200221-00003-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Fitton, Andrew</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Quinolones</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1992</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary The fluoroquinolones represent a relatively new class of antibiotics with outstanding therapeutic potential, attributable to their broad spectrum of antimicrobial activity and favourable tissue distribution. They are highly active against most Gram-negative pathogens, as well as Staphylococcus aureus and coagulase-negative staphylococci. In addition, the fluoroquinolones have useful pharmacokinetic properties: they are orally active, and their lipophilicity and low degree of plasma protein binding allow for excellent tissue penetration and concentrations, as reflected in their particularly large apparent volumes of distribution. Infections due to aerobic Gram-negative pathogens are considered those most susceptible to the quinolones. Disease indications in which these agents appear to offer the greatest therapeutic advantage over currently available alternatives include the following: complicated urinary tract infections (particularly those caused by Pseudomonas aeruginosa or resistant Gram-negative microorganisms); suspected bacterial gastroenteritis; eradication of Salmonella typhi from the faeces in known carriers; P. aeruginosa-associated respiratory exacerbation in patients with cystic fibrosis; and chronic Gram-negative bacterial osteomyelitis. Direct comparisons of the various quinolones are too limited to date to provide clear therapeutic options. Nevertheless, this class of compounds is likely to play a major role in providing effective oral therapy for conditions that have previously required prolonged parenteral treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Fluoroquinolones</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ofloxacin</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Norfloxacin</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chlamydia Trachomatis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antimicrobial Chemotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Clinical pharmacokinetics</subfield><subfield code="d">Berlin [u.a.] : Springer, 1976</subfield><subfield code="g">22(1992), Suppl 1 vom: Juni, Seite 1-11</subfield><subfield code="w">(DE-627)327644974</subfield><subfield code="w">(DE-600)2043781-X</subfield><subfield code="x">1179-1926</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:22</subfield><subfield code="g">year:1992</subfield><subfield code="g">number:Suppl 1</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:1-11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00003088-199200221-00003</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.00</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">22</subfield><subfield code="j">1992</subfield><subfield code="e">Suppl 1</subfield><subfield code="c">06</subfield><subfield code="h">1-11</subfield></datafield></record></collection>
|
| author |
Fitton, Andrew |
| spellingShingle |
Fitton, Andrew ddc 610 bkl 44.00 bkl 44.40 misc Fluoroquinolones misc Ofloxacin misc Norfloxacin misc Chlamydia Trachomatis misc Antimicrobial Chemotherapy The Quinolones |
| authorStr |
Fitton, Andrew |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)327644974 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1179-1926 |
| topic_title |
610 ASE 44.00 bkl 44.40 bkl The Quinolones Fluoroquinolones (dpeaa)DE-He213 Ofloxacin (dpeaa)DE-He213 Norfloxacin (dpeaa)DE-He213 Chlamydia Trachomatis (dpeaa)DE-He213 Antimicrobial Chemotherapy (dpeaa)DE-He213 |
| topic |
ddc 610 bkl 44.00 bkl 44.40 misc Fluoroquinolones misc Ofloxacin misc Norfloxacin misc Chlamydia Trachomatis misc Antimicrobial Chemotherapy |
| topic_unstemmed |
ddc 610 bkl 44.00 bkl 44.40 misc Fluoroquinolones misc Ofloxacin misc Norfloxacin misc Chlamydia Trachomatis misc Antimicrobial Chemotherapy |
| topic_browse |
ddc 610 bkl 44.00 bkl 44.40 misc Fluoroquinolones misc Ofloxacin misc Norfloxacin misc Chlamydia Trachomatis misc Antimicrobial Chemotherapy |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Clinical pharmacokinetics |
| hierarchy_parent_id |
327644974 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Clinical pharmacokinetics |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)327644974 (DE-600)2043781-X |
| title |
The Quinolones |
| ctrlnum |
(DE-627)SPR03303950X (SPR)00003088-199200221-00003-e |
| title_full |
The Quinolones |
| author_sort |
Fitton, Andrew |
| journal |
Clinical pharmacokinetics |
| journalStr |
Clinical pharmacokinetics |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
1992 |
| contenttype_str_mv |
txt |
| container_start_page |
1 |
| author_browse |
Fitton, Andrew |
| container_volume |
22 |
| class |
610 ASE 44.00 bkl 44.40 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Fitton, Andrew |
| doi_str_mv |
10.2165/00003088-199200221-00003 |
| dewey-full |
610 |
| title_sort |
quinolones |
| title_auth |
The Quinolones |
| abstract |
Summary The fluoroquinolones represent a relatively new class of antibiotics with outstanding therapeutic potential, attributable to their broad spectrum of antimicrobial activity and favourable tissue distribution. They are highly active against most Gram-negative pathogens, as well as Staphylococcus aureus and coagulase-negative staphylococci. In addition, the fluoroquinolones have useful pharmacokinetic properties: they are orally active, and their lipophilicity and low degree of plasma protein binding allow for excellent tissue penetration and concentrations, as reflected in their particularly large apparent volumes of distribution. Infections due to aerobic Gram-negative pathogens are considered those most susceptible to the quinolones. Disease indications in which these agents appear to offer the greatest therapeutic advantage over currently available alternatives include the following: complicated urinary tract infections (particularly those caused by Pseudomonas aeruginosa or resistant Gram-negative microorganisms); suspected bacterial gastroenteritis; eradication of Salmonella typhi from the faeces in known carriers; P. aeruginosa-associated respiratory exacerbation in patients with cystic fibrosis; and chronic Gram-negative bacterial osteomyelitis. Direct comparisons of the various quinolones are too limited to date to provide clear therapeutic options. Nevertheless, this class of compounds is likely to play a major role in providing effective oral therapy for conditions that have previously required prolonged parenteral treatment. |
| abstractGer |
Summary The fluoroquinolones represent a relatively new class of antibiotics with outstanding therapeutic potential, attributable to their broad spectrum of antimicrobial activity and favourable tissue distribution. They are highly active against most Gram-negative pathogens, as well as Staphylococcus aureus and coagulase-negative staphylococci. In addition, the fluoroquinolones have useful pharmacokinetic properties: they are orally active, and their lipophilicity and low degree of plasma protein binding allow for excellent tissue penetration and concentrations, as reflected in their particularly large apparent volumes of distribution. Infections due to aerobic Gram-negative pathogens are considered those most susceptible to the quinolones. Disease indications in which these agents appear to offer the greatest therapeutic advantage over currently available alternatives include the following: complicated urinary tract infections (particularly those caused by Pseudomonas aeruginosa or resistant Gram-negative microorganisms); suspected bacterial gastroenteritis; eradication of Salmonella typhi from the faeces in known carriers; P. aeruginosa-associated respiratory exacerbation in patients with cystic fibrosis; and chronic Gram-negative bacterial osteomyelitis. Direct comparisons of the various quinolones are too limited to date to provide clear therapeutic options. Nevertheless, this class of compounds is likely to play a major role in providing effective oral therapy for conditions that have previously required prolonged parenteral treatment. |
| abstract_unstemmed |
Summary The fluoroquinolones represent a relatively new class of antibiotics with outstanding therapeutic potential, attributable to their broad spectrum of antimicrobial activity and favourable tissue distribution. They are highly active against most Gram-negative pathogens, as well as Staphylococcus aureus and coagulase-negative staphylococci. In addition, the fluoroquinolones have useful pharmacokinetic properties: they are orally active, and their lipophilicity and low degree of plasma protein binding allow for excellent tissue penetration and concentrations, as reflected in their particularly large apparent volumes of distribution. Infections due to aerobic Gram-negative pathogens are considered those most susceptible to the quinolones. Disease indications in which these agents appear to offer the greatest therapeutic advantage over currently available alternatives include the following: complicated urinary tract infections (particularly those caused by Pseudomonas aeruginosa or resistant Gram-negative microorganisms); suspected bacterial gastroenteritis; eradication of Salmonella typhi from the faeces in known carriers; P. aeruginosa-associated respiratory exacerbation in patients with cystic fibrosis; and chronic Gram-negative bacterial osteomyelitis. Direct comparisons of the various quinolones are too limited to date to provide clear therapeutic options. Nevertheless, this class of compounds is likely to play a major role in providing effective oral therapy for conditions that have previously required prolonged parenteral treatment. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 |
| container_issue |
Suppl 1 |
| title_short |
The Quinolones |
| url |
https://dx.doi.org/10.2165/00003088-199200221-00003 |
| remote_bool |
true |
| ppnlink |
327644974 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.2165/00003088-199200221-00003 |
| up_date |
2024-07-03T16:13:17.716Z |
| _version_ |
1803575044571398144 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR03303950X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519182346.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1992 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00003088-199200221-00003</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR03303950X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00003088-199200221-00003-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Fitton, Andrew</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Quinolones</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1992</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary The fluoroquinolones represent a relatively new class of antibiotics with outstanding therapeutic potential, attributable to their broad spectrum of antimicrobial activity and favourable tissue distribution. They are highly active against most Gram-negative pathogens, as well as Staphylococcus aureus and coagulase-negative staphylococci. In addition, the fluoroquinolones have useful pharmacokinetic properties: they are orally active, and their lipophilicity and low degree of plasma protein binding allow for excellent tissue penetration and concentrations, as reflected in their particularly large apparent volumes of distribution. Infections due to aerobic Gram-negative pathogens are considered those most susceptible to the quinolones. Disease indications in which these agents appear to offer the greatest therapeutic advantage over currently available alternatives include the following: complicated urinary tract infections (particularly those caused by Pseudomonas aeruginosa or resistant Gram-negative microorganisms); suspected bacterial gastroenteritis; eradication of Salmonella typhi from the faeces in known carriers; P. aeruginosa-associated respiratory exacerbation in patients with cystic fibrosis; and chronic Gram-negative bacterial osteomyelitis. Direct comparisons of the various quinolones are too limited to date to provide clear therapeutic options. Nevertheless, this class of compounds is likely to play a major role in providing effective oral therapy for conditions that have previously required prolonged parenteral treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Fluoroquinolones</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ofloxacin</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Norfloxacin</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chlamydia Trachomatis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antimicrobial Chemotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Clinical pharmacokinetics</subfield><subfield code="d">Berlin [u.a.] : Springer, 1976</subfield><subfield code="g">22(1992), Suppl 1 vom: Juni, Seite 1-11</subfield><subfield code="w">(DE-627)327644974</subfield><subfield code="w">(DE-600)2043781-X</subfield><subfield code="x">1179-1926</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:22</subfield><subfield code="g">year:1992</subfield><subfield code="g">number:Suppl 1</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:1-11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00003088-199200221-00003</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.00</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">22</subfield><subfield code="j">1992</subfield><subfield code="e">Suppl 1</subfield><subfield code="c">06</subfield><subfield code="h">1-11</subfield></datafield></record></collection>
|
| score |
7.3982906 |